Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

(2015) F.S. Hodi et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune modulation for cancer therapy

(2014) J Naidoo et al.   BRITISH JOURNAL OF CANCER

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune hepatitis: the role of environmental risk factors: a population-based study

(2013) Jing H. Ngu et al.   Hepatology International

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

(2011) Katarzyna D. Chmiel et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

(2010) Kaan Harmankaya et al.   MEDICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY